Sanofi-Aventis Sa (NYSE:SNY).
Raymond James & Associates reports that it lowered its investment in Sanofi-Aventis Sa by 489,150 shares as of the end of the last quarter. Its position was valued at $116,845,000 a decrease of $19,023,000 as of the end of the quarter.
The following firms have recently changed their position in SNY. As of quarter end Edmond De Rothschild Holding S.a. had bought 750 shares growing its holdings by 25.9%. The value of the investment in Sanofi-Aventis Sa increased from $140,000 to $180,000 a change of 28.6% since the last quarter. Greenleaf Trust grew its stake by buying 3,951 shares an increase of 24.0% as of 09/30/2017. Greenleaf Trust owns 20,381 shares valued at $1,015,000. The total value of its holdings increased 29.0%.
Baird Financial Group, Inc. downsized its investment by selling 58,023 shares a decrease of 16.7% from 06/30/2017 to 09/30/2017. Baird Financial Group, Inc. claims 288,431 shares worth $14,361,000. The value of the position overall is down by 13.5%.
September 15 investment analysts at J P Morgan Chase & Co reiterated a “Neutral” rating on the stock. September 1 investment analysts at Argus held the company rating at “Buy” with a current price target of $55.00.
On August 1 Cowen and Company made no change to the company rating of “Market Perform” projecting a price of $52.00.
In the market the company is trading up from yesterday’s close of 44.65. The P/E ratio is currently 20.97 and the market cap of the company is 112.73B. In the last earnings report the EPS was $2.13 with 1.26B shares now outstanding.
Investors are feeling more bullish on shares of the company recently as shown by the fall in short interest. The company experienced a fall in short interest of -9.03% as of October 13, 2017 from the last reporting period. Short interest fell 186,375 over that timeframe. Days to cover decreased from 2.0 to 1.0 and the short interest percentage is 0.00% as of October 13.